Related Experiment Video

Updated: Jun 17, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients

M Taheri1, F Mahjoubi, R Omranipour

  • 1Departament of Clinical Genetics, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.

Genetics and Molecular Research : GMR
|January 19, 2010
PubMed

Insights

Multidrug resistance (MDR) in cancer chemotherapy can be influenced by MDR1 gene variations. This study found that while MDR1 C3435T polymorphism didn't differ between groups, it was associated with altered MDR1 gene expression in Iranian breast cancer patients.

Area of Science:

  • Genetics
  • Oncology
  • Pharmacogenomics

Background:

  • Multidrug resistance (MDR) is a major challenge in cancer chemotherapy.
  • Over-expression of the MDR1 gene, encoding P-glycoprotein (P-gp), is a key mechanism of MDR.
  • MDR1 gene polymorphisms may affect P-gp levels and influence drug resistance.

Purpose of the Study:

  • To investigate the association between the MDR1 gene C3435T polymorphism and its expression in Iranian breast cancer patients.
  • To explore the role of this polymorphism in the development of chemotherapy resistance.

Main Methods:

  • PCR-RFLP was employed to genotype the MDR1 C3435T polymorphism in 54 breast cancer patients and 50 healthy controls.
  • Real-time quantitative PCR was used to determine MDR1 gene expression levels.

Main Results:

  • No significant difference in the frequency of the MDR1 C3435T polymorphism was observed between breast cancer patients and healthy individuals.
  • A significant association was found between MDR1 gene expression levels and the C3435T polymorphism in breast cancer patients.

Conclusions:

  • The MDR1 C3435T polymorphism may contribute to chemotherapy resistance in breast cancer by modulating MDR1 gene expression.
  • Further research is warranted to elucidate the precise mechanisms linking this polymorphism to drug resistance in cancer treatment.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mismatch Repair01:36

Mismatch Repair

Overview
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...